Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells 110,842 Shares of Stock
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 110,842 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average...
MarketBeat·2h ago
More News
Why Phibro (PAHC) International Revenue Trends Deserve Your Attention
Explore how Phibro's (PAHC) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
DOCS beats Q3 EPS and revenue estimates, but shares plunge 38.5% after hours as margins contract and FY26 revenue guidance is lowered.
Zacks·3d ago
3 Reasons Growth Investors Will Love Phibro (PAHC)
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
Zacks·3d ago
MCK Q3 Earnings & Sales Top Estimates, 2026 View Up
McKesson beats Q3 EPS and revenue estimates, raises fiscal 2026 guidance, and delivers broad-based growth led by oncology, specialty distribution and technology.
Zacks·3d ago
Phibro Animal Health (PAHC) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·3d ago
Insider Selling: Phibro Animal Health (NASDAQ:PAHC) CEO Sells $400,600.20 in Stock
Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) CEO Jack Bendheim sold 9,660 shares of Phibro Animal Health stock in a transaction that occurred on Tuesday, February 3rd. The shares...
MarketBeat·3d ago
Phibro Animal Health Corporation $PAHC Shares Sold by Ranger Investment Management L.P.
Ranger Investment Management L.P. cut its stake in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 16.2% in the third quarter, according to its most recent 13F filing with the...
MarketBeat·3d ago
Phibro Animal Health Corporation (PAHC) Hit a 52 Week High, Can the Run Continue?
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks·3d ago
QGEN's Q4 Earnings Meet Estimates, Revenues Up Y/Y, Stock Down
QIAGEN shares decline as Q4 earnings meet estimates and revenues beat, with margin contraction and cautious 2026 guidance in focus.